Valeo Financial Advisors LLC Has $891,000 Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Valeo Financial Advisors LLC trimmed its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 19.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,251 shares of the biopharmaceutical company’s stock after selling 296 shares during the period. Valeo Financial Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $891,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Klingenstein Fields & Co. LP increased its stake in Regeneron Pharmaceuticals by 1,083.7% in the 4th quarter. Klingenstein Fields & Co. LP now owns 6,806 shares of the biopharmaceutical company’s stock valued at $4,848,000 after buying an additional 6,231 shares during the last quarter. Banque Pictet & Cie SA acquired a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at $4,496,000. V Square Quantitative Management LLC increased its stake in Regeneron Pharmaceuticals by 11.9% in the 4th quarter. V Square Quantitative Management LLC now owns 1,489 shares of the biopharmaceutical company’s stock valued at $1,061,000 after buying an additional 158 shares during the last quarter. Vontobel Holding Ltd. increased its stake in Regeneron Pharmaceuticals by 56.1% in the 4th quarter. Vontobel Holding Ltd. now owns 6,458 shares of the biopharmaceutical company’s stock valued at $4,600,000 after buying an additional 2,322 shares during the last quarter. Finally, Asset Management One Co. Ltd. increased its stake in Regeneron Pharmaceuticals by 6.2% in the 4th quarter. Asset Management One Co. Ltd. now owns 59,980 shares of the biopharmaceutical company’s stock valued at $42,730,000 after buying an additional 3,504 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. Wells Fargo & Company lowered their price target on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a research note on Friday, January 10th. Oppenheimer decreased their price objective on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a research report on Wednesday, November 6th. Evercore ISI decreased their price objective on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a research report on Thursday, October 24th. Bank of America reissued an “underperform” rating and issued a $565.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 10th. Finally, Canaccord Genuity Group downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 17th. One research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $973.13.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $673.60 on Monday. The firm has a 50-day moving average price of $706.92 and a two-hundred day moving average price of $896.16. The company has a market capitalization of $74.02 billion, a P/E ratio of 17.60, a P/E/G ratio of 2.38 and a beta of 0.08. The company has a quick ratio of 4.46, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12-month low of $642.00 and a 12-month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating the consensus estimate of $11.21 by $0.86. The company had revenue of $3.79 billion during the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period in the previous year, the company earned $11.86 EPS. Analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 36.67 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be given a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.52%. The ex-dividend date of this dividend is Thursday, February 20th.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.